AstraZeneca Gets CDSCO Nod For Durvalumab Use In Uterine Cancer

AstraZeneca Pharma India Ltd. has received approval from the Central Drugs Standard Control Organisation to import and sell Durvalumab for an additional indication.

The drug, in combination with carboplatin and paclitaxel, is now approved as a first-line treatment for adults with primary advanced or recurrent endometrial cancer eligible for systemic therapy.